Application
Epilepsy affects over 65 million people worldwide. Approximately 30% of epilepsy patients do not respond to existing drugs. Additionally, the available drugs often come with multiple adverse effects and mainly address seizure symptoms rather than modifying the underlying causes of epilepsy.
Therefore, there is a critical need for more effective and well-tolerated treatments. Developing drugs that can modify the underlying disease, delay epilepsy onset, or even reverse disease progression is crucial to addressing this challenge.
Our Innovation
We use a water-soluble tripeptide, designed to mimic the function of a protein that plays a crucial role in reducing oxidative stress and maintaining cellular redox balance.
We explore the efficacy of this very small peptide to attenuate epilepsy development (anti-epileptogenic effect) and its anti-seizure effect in established chronic epilepsy.
Advantages
- Our compound exhibits a dual effect by demonstrating antioxidant properties and orchestrating anti-inflammatory responses.
- The treatment in rats led to a significant decrease in the normalized seizure frequency compared to the vehicle-treated group. Additionally, the normalized cumulative number of seizures post-treatment exhibited a significant reduction in the treatment group compared to the vehicle-treated rats.
Opportunity
Our compound has the potential for practical applications as an anti-epileptogenic agent, preventing the development of epilepsy, and as an anti-seizure medication for managing chronic epilepsy.
This novel treatment shows great potential for developing commercial products in the field of anti-epileptic drugs. We are seeking collaboration with pharmaceutical companies that specialize in developing anti-epileptic medications.
